Atai Says Its Depression Treatment Failed In A Mid-stage Clinical Trial -- MarketWatch

MarketWatch · 01/06/2023 13:51
For more from MarketWatch:

Shares of Atai Life Sciences NV (ATAI) tumbled about 44% in premarket trading on Friday after the company said a Phase 2a clinical trial evaluating a ketamine therapy for treatment-resistant depression did not meet the primary endpoint. Atai's stock has declined 60.1% over the past year, while the S&P 500 is down 19.0%.

-Jaimy Lee

(END) Dow Jones Newswires

January 06, 2023 08:51 ET (13:51 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.